Kathleen Alyce Waters Sells 15,405 Shares of DaVita (NYSE:DVA) Stock

DaVita Inc. (NYSE:DVA) insider Kathleen Alyce Waters sold 15,405 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the sale, the insider directly owned 109,194 shares in the company, valued at approximately $22,756,029.60. This represents a 12.36% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

DaVita Price Performance

DVA stock opened at $207.65 on Friday. The business has a fifty day moving average price of $181.04 and a 200 day moving average price of $148.78. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $213.44. The stock has a market capitalization of $13.33 billion, a price-to-earnings ratio of 19.26, a P/E/G ratio of 0.69 and a beta of 0.91.

DaVita (NYSE:DVA) last announced its earnings results on Tuesday, May 5th. The company reported $2.87 EPS for the quarter, topping the consensus estimate of $2.33 by $0.54. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The company had revenue of $3.42 billion for the quarter, compared to analysts’ expectations of $3.36 billion. During the same quarter in the prior year, the business earned $2.00 earnings per share. The business’s revenue for the quarter was up 6.0% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, equities analysts expect that DaVita Inc. will post 15.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on DVA shares. Weiss Ratings reissued a “hold (c+)” rating on shares of DaVita in a report on Monday, June 8th. Zacks Research upgraded shares of DaVita from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. UBS Group increased their price target on shares of DaVita from $190.00 to $235.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Truist Financial raised their price target on shares of DaVita from $158.00 to $205.00 and gave the company a “hold” rating in a report on Friday, May 8th. Finally, Wall Street Zen upgraded shares of DaVita from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, DaVita has an average rating of “Hold” and an average target price of $199.17.

Institutional Trading of DaVita

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. NewEdge Advisors LLC raised its stake in shares of DaVita by 20.8% during the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock worth $78,000 after buying an additional 88 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in DaVita by 19.1% in the first quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock valued at $27,403,000 after buying an additional 28,739 shares during the period. Cerity Partners LLC boosted its stake in DaVita by 7.0% in the second quarter. Cerity Partners LLC now owns 2,638 shares of the company’s stock valued at $376,000 after acquiring an additional 172 shares during the last quarter. Bank of Nova Scotia grew its holdings in DaVita by 3.8% during the 2nd quarter. Bank of Nova Scotia now owns 4,813 shares of the company’s stock worth $686,000 after acquiring an additional 176 shares during the period. Finally, Natixis grew its holdings in DaVita by 80.9% during the 2nd quarter. Natixis now owns 7,297 shares of the company’s stock worth $1,039,000 after acquiring an additional 3,264 shares during the period. 90.12% of the stock is owned by institutional investors.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.